相关实验视频
Updated: Jul 14, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
645
甲福明对非糖尿病心力衰竭患者氧化应激和左心室几何学的影响:一项随机对照试验
Ahmed M Kamel1, Batool Ismail2, Gamal Abdel Hafiz2
1Clinical Pharmacy Department, Faculty of Pharmacy Cairo University, Cairo, Egypt.
Metabolic syndrome and related disorders
|October 10, 2023
概括
甲胺改善了抗氧化能力,并防止了非糖尿病心力衰竭患者的不良心脏重塑,心脏衰竭患者的排泄分数减少. 需要进一步的研究来探索这些潜在的好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 越来越多的人对治疗心血管疾病的梅特福明的兴趣.
- 在非糖尿病心力衰竭 (HF) 患者中对甲福明的研究有限,特别是在氧化应激方面.
- 需要调查甲福明在改善氧化应激和左心室重塑中HF中的作用.
研究的目的:
- 调查甲福明对氧化应激和左心室重塑在非糖尿病心力衰竭和减少喷射率 (HFrEF) 的患者的影响.
主要方法:
- 一项随机对照试验,涉及70名HFrEF患者,随机分配给甲福林或标准护理 (SOC) 6个月.
- 评估了总抗氧化能力 (TAC),甲酸 (MDA) 和左心室质量指数 (LVMI) 的变化.
- 除了标准的HF治疗之外,在甲福明和SOC组之间比较结果.
主要成果:
- 与SOC相比,甲胺显著增加了TAC (P=0.007).
- 与SOC相比,甲胺保持了LVMI (P=0.014) 和降低了快速血葡萄糖 (P=0.047) .
- 两组之间MDA,左心室喷射率 (LVEF) 或血压变化没有显著差异.
结论:
- 甲胺治疗改善了TAC,并预防了没有糖尿病的HFrEF患者的LVMI增加.
- 这些发现表明,在没有糖尿病的HF患者中,甲福明的潜在益处值得进一步研究.
- 在临床试验.gov注册:NCT05177588.8.
更多相关视频
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
218
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.3K
相关概念视频
01:30Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
01:22Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
01:30Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19